AGT and type 2 diabetes mellitus: Large type 2 diabetes trials, such as the RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) (58), the IDNT (Irbesartan in Diabetic Nephropathy Trial) (59), and the MARVAL (MicroAlbuminuria Reduction With VALsartan) Study (60) have linked the use of renin-angiotensin system (RAS) blockers to higher chances of regression of albuminuria compared to placebo.